Art

J-GLOBAL ID：202002215690933497   Reference number：20A2344581

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

エフェクターと制御性T細胞間のPD-1発現バランスはPD-1遮断療法の臨床的有効性を予測する【JST・京大機械翻訳】

Author (36)： Kumagai Shogo (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Kumagai Shogo (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Togashi Yosuke (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Kamada Takahiro (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Kamada Takahiro (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Sugiyama Eri (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Sugiyama Eri (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Nishinakamura Hitomi (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Takeuchi Yoshiko (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Vitaly Kochin (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Itahashi Kota (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Maeda Yuka (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Matsui Shigeyuki (Department of Biostatics, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Shibahara Takuma (Research and Development Group, Hitachi Ltd., Tokyo, Japan) ,  Yamashita Yasuho (Research and Development Group, Hitachi Ltd., Tokyo, Japan) ,  Irie Takuma (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Tsuge Ayaka (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Tsuge Ayaka (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Fukuoka Shota (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Kawazoe Akihito (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Udagawa Hibiki (Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Kirita Keisuke (Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Aokage Keiju (Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan) ,  Ishii Genichiro (Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan) ,  Kuwata Takeshi (Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan) ,  Nakama Kenta (Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Kawazu Masahito (Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan) ,  Ueno Toshihide (Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan) ,  Yamazaki Naoya (Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Goto Koichi (Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Tsuboi Masahiro (Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan) ,  Mano Hiroyuki (Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan) ,  Doi Toshihiko (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Shitara Kohei (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ,  Nishikawa Hiroyoshi (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan) ,  Nishikawa Hiroyoshi (Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
Material： Nature Immunology  (Nat Immunol)
Volume： 21  Issue： 11  Page： 1346-1358  Publication year： 2020 
JST Material Number： W1330A  ISSN： 1529-2908  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Abstract/Point： Abstract: Immune checkpoint bl...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2344581&from=J-GLOBAL&jstjournalNo=W1330A") }}

Thesaurus term： tumor ,  Proteins ,  immunosuppression ,  dysfunction ,  effectiveness ,  tumor regression ,  effector ,  biomarker ,  *regulatory T cell ,  CD8 positive T cell ,  Ligands ,  programmed cell death ,  Tumor Microenvironment ,  *Programmed Cell Death 1 Receptor ,  reaction ,  immune response ,  suppression and control
Semi thesaurus term： 癌治療 , 【Automatic Indexing@JST】

JST classification (2)： Immunological reaction in general  (ED03010T) ,  Infectious immunity  (ED03030P)

Terms in the title (8)： エフェクター ,  制御性T細胞 ,  発現 ,  バランス ,  遮断 ,  療法 ,  臨床的有効性 ,  予測